1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Kineta, Inc. - Product Pipeline Review - 2015

Kineta, Inc. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 28 pages

Kineta, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Kineta, Inc. - Product Pipeline Review - 2015’, provides an overview of the Kineta, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Kineta, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Kineta, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Kineta, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Kineta, Inc.’s pipeline products

Reasons to buy

- Evaluate Kineta, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Kineta, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Kineta, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Kineta, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kineta, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Kineta, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Kineta, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Kineta, Inc. Snapshot 5
Kineta, Inc. Overview 5
Key Information 5
Key Facts 5
Kineta, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Kineta, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Kineta, Inc. - Pipeline Products Glance 11
Kineta, Inc. - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Kineta, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Kineta, Inc. - Drug Profiles 13
dalazatide 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Innate Immune Adjuvants 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
rOAS 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Small Molecule to Agonize IRF-3 for Viral Infections 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
U-2902 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Kineta, Inc. - Pipeline Analysis 19
Kineta, Inc. - Pipeline Products by Target 19
Kineta, Inc. - Pipeline Products by Route of Administration 20
Kineta, Inc. - Pipeline Products by Molecule Type 21
Kineta, Inc. - Pipeline Products by Mechanism of Action 22
Kineta, Inc. - Recent Pipeline Updates 23
Kineta, Inc. - Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 27
Disclaimer 28

List of Tables
Kineta, Inc., Key Information 5
Kineta, Inc., Key Facts 5
Kineta, Inc. - Pipeline by Indication, 2015 7
Kineta, Inc. - Pipeline by Stage of Development, 2015 9
Kineta, Inc. - Monotherapy Products in Pipeline, 2015 10
Kineta, Inc. - Phase I, 2015 11
Kineta, Inc. - Preclinical, 2015 12
Kineta, Inc. - Pipeline by Target, 2015 19
Kineta, Inc. - Pipeline by Route of Administration, 2015 20
Kineta, Inc. - Pipeline by Molecule Type, 2015 21
Kineta, Inc. - Pipeline Products by Mechanism of Action, 2015 22
Kineta, Inc. - Recent Pipeline Updates, 2015 23

List of Figures
Kineta, Inc. - Pipeline by Top 10 Indication, 2015 7
Kineta, Inc. - Pipeline by Stage of Development, 2015 9
Kineta, Inc. - Monotherapy Products in Pipeline, 2015 10
Kineta, Inc. - Pipeline by Top 10 Target, 2015 19
Kineta, Inc. - Pipeline by Top 10 Route of Administration, 2015 20
Kineta, Inc. - Pipeline by Top 10 Molecule Type, 2015 21
Kineta, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) ...

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.